{"nctId":"NCT03426267","briefTitle":"Evaluation of Efficacy and Safety of SDN-037","startDateStruct":{"date":"2018-09-28","type":"ACTUAL"},"conditions":["Inflammation and Pain Associated With Ocular Surgery"],"count":325,"armGroups":[{"label":"SDN-037","type":"EXPERIMENTAL","interventionNames":["Drug: SDN-037"]},{"label":"vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"SDN-037","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Be at least 2 years of age on the date of assent or 18 years of age at the date of consent\n2. Be able and willing to follow study instructions and complete all required visits\n3. Females of childbearing potential must not be pregnant (as confirmed by a negative urine pregnancy test\n4. Able to self-instill the IP or have a caregiver available to instil all doses of the IP\n\nExclusion Criteria:\n\n1. Any known allergy or hypersensitivity to difluprednate therapy\n2. An acute ocular infection (bacterial, viral or fungal) or active ocular inflammation in the study eye\n3. Any active corneal pathology noted in the study eye\n4. Currently suffering from alcohol and/or drug abuse","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Subjects With an Anterior Chamber Cell Grade of 0 at Day 15","description":"Grade Cell Count 0 0\n\n1. 1-10\n2. 11-20\n3. 21-50\n4. \\> 50\n\nACC grade of 0 at the Day 15 visit was considered a responder to therapy ACC score of \\>0 at Day 15 visit was considered a failure (or non-responder)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Subjects Who Achieve a Pain Score of 0 at Day 15","description":"Pain was assessed using a visual analog scale (VAS). The Visual Analog Scale (VAS) uses a 100 mm (10 cm) line (0 = absent \\>100 = maximum). A 0 indicates an absence of pain A higher score indicates greater pain intensity.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"151","spread":null},{"groupId":"OG001","value":"106","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":154},"commonTop":["Anterior chamber cell","Anterior chamber flare","Visual acuity reduced","Conjunctival hyperaemia","Corneal oedema"]}}}